Amgen Inc. (AMGN) News
Filter AMGN News Items
AMGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMGN News Highlights
- AMGN's 30 day story count now stands at 25.
- Over the past 20 days, the trend for AMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about AMGN are DOW, DRUG and CELL.
Latest AMGN News From Around the Web
Below are the latest news stories about AMGEN INC that investors may wish to consider to help them evaluate AMGN as an investment opportunity.
Dow Jones Today: Apple Headset Can’t Lift IndexThe Dow Jones Industrial Average fell 0.6%, or about 200 points, as markets cooled off from Friday's blistering rally. Amgen rose more than any other stock, but Intel led the index lower. |
Even Mark Cuban Can’t Fix This Broken Drug SystemCoherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices. |
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecastJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting. Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022. Its patents begin to expire this year, opening the door to a cheaper biosimilar entering the market, and raising expectations that the company would need to lower the $13,000 per month price of Stelara. |
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. The research presented reinforces the efficacy of LUMAKRAS®/LUMYKRAS® (sotorasib) in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Additionally, data from SCA |
3 Undervalued Biotech Stocks to Buy Before They Blast OffFundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. |
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The SpreeBig Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand. |
Possible Bearish Signals With Amgen Insiders Disposing Stock \Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have... |
Dow Jones Today: Debt Vote Drives Index HigherThe Dow Jones Industrial Average moved higher by more than 0.5%, or 153 points, as investors celebrated the House of Representatives passage of the debt-ceiling bill, which now goes to the Senate. |
Why AbbVie and Amgen Are Moving Lower TodayShares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. Coherus' biosimilar will be branded as Yusimry. |
Is Amgen a Good Dividend Stock?Biotech pioneer Amgen (NASDAQ: AMGN) has several key elements of a good dividend stock. Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid. Amgen is moving into a highly uncertain period, characterized by high levels of competition from biosimilars (generic biologics) for many of its aging blockbusters, pushback from the Federal Trade Commission over its proposed takeover of Horizon Therapeutics (NASDAQ: HZNP), and serious question marks surrounding the rationale of this $28 billion buyout. |